Abstract
Clostridioides difficile infection (CDI) remains a devastating infection both in hospital settings and in the community. While a number of antibiotics have anti-C. difficile activity, fidaxomicin is unique as a minimally absorbed antibiotic with narrow spectrum of activity. These features make it an appealing option for pediatric CDI to balance safety and efficacy. The purpose of this structured review was to outline the clinical evidence for safety and efficacy of fidaxomicin for pediatric CDI. A structured literature search was performed to identify relevant clinical data. Fidaxomicin is similarly effective to oral vancomycin with a lower rate of recurrent CDI. There were no serious safety signals reported with fidaxomicin. In conclusion, fidaxomicin is a safe and effective treatment option for pediatric CDI.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 91-98 |
| Number of pages | 8 |
| Journal | Clinical Pharmacology: Advances and Applications |
| Volume | 14 |
| DOIs | |
| State | Published - 2022 |
Bibliographical note
Funding Information:Meredith B Oliver has no conflicts of interest to disclose. Byron P Vaughn has received consulting fees from Prometheus Laboratories and Abbvie as well as grant support from Takeda, Genentech, Diasorin, Pfizer and Celgene.
Publisher Copyright:
© 2022 Oliver and Vaughn.
Keywords
- Dificid
- colitis
- diarrhea
- microbiota
PubMed: MeSH publication types
- Journal Article
- Review